Express US$360 million to help develop innovative treatments for Parkinson's disease, and Ipsen capsules obtain dopamine receptor antagonists

▎The content team editors of WuXi AppTec Ipsen and IRLAB have jointly announced that the two parties have signed a licensing agreement under which Ipsen will receive the global development and promotion rights of the innovative dopamine D3 receptor antagonist mesdopetam
.

This innovative therapy is currently being tested in a phase 2b clinical trial for the treatment of dyskinesias in patients with Parkinson's disease after receiving levodopa treatment
.

Parkinson's disease (PD) is a progressive neurodegenerative disease caused by the gradual loss of brain cells that produce the neurotransmitter dopamine
.

The decline in dopamine in the brain leads to a wide range of motor and non-motor symptoms
.

Since the 1970s, the main treatment for PD patients has been levodopa
.

However, over time, levodopa may cause involuntary, uncontrolled movements called dyskinesia
.

The press release pointed out that about 40-50% of PD patients will experience levodopa-induced dyskinesia after receiving dopamine replacement therapy for 5 years, which greatly affects their quality of life
.

Mesdopetam is an innovative oral dopamine D3 receptor antagonist
.

Previous genetic studies have shown that dopamine D3 receptors are associated with increased risk of involuntary movement
.

In the completed Phase 2a clinical trial, PD patients receiving mesdopetam have achieved a dose-dependent reduction in dyskinesia, resulting in a significant increase in the "Good ON" time
.

In patients in the mesdopetam group who received the optimal therapeutic dose, the Good ON time increased by 5.
6 hours per day, compared with 1 hour in the control group (p<0.
002)
.

▲The molecular structure of Mesdopetam (picture source: PubChem) Mesdopetam is also used in clinical trials to treat psychosis in PD patients
.

According to the agreement, IRLAB will receive an upfront payment of US$28 million and is eligible to receive a development, supervision and promotion milestone payment of US$335 million
.

IRLAB will continue to be responsible for phase 2b clinical trials
.

Ipsen will initiate preparations for Phase 3 clinical trials and will be responsible for subsequent clinical development and promotion activities
.

Dr.
Howard Mayer, Executive Vice President and Head of Research and Development of Ipsen, said: “We are very pleased to reach a licensing agreement with IRLAB
.

Through cooperation with IRLAB, we will strive to bring mesdopetam to Parkinson’s who suffer from levodopa-induced movement disorders.
Sick patient
.

"Reference: [1] Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson's disease.
Retrieved July 16, 2021, from https:// and-irlab-enter-exclusive-worldwide-licensing-agreement-aimed-to-improve-the-lives-of-people-living-with-parkinsons-disease/[2] IRLAB's Phase IIb/III Study in Parkinson's disease to Target Good ON.
Retrieved July 16, 2021, from https:// : This article aims to introduce the progress of medical and health research, not to recommend treatment plans
.

If you need guidance on treatment plans, please go to a regular hospital for treatment
.